Abstract
Background and hypothesis: The predictive value of specific markers of infection and autoimmunity for coronary events, such as the effects of statins on inflammation, is still controversial.
Methods: A case‐control design was used to compare C‐reactive protein (CRP) levels, seropositivity for Chlamydia pneumoniae and Helicobacter pylori, and anti‐oxidized low‐density lipoprotein (oxLDL) antibody levels in prerandomization blood samples from 129 participants in the Scandinavian Simvastatin Survival Study who died (cases), and from 129 matched participants who were alive during 5‐year follow‐up (controls).
Results: Patients with CRP levels in the highest quartile had an increased risk of death compared with those in the first through third quartile (odds ratio [OR] = 2.51, 95% confidence interval [CI] 1.3‐4.8). Seropositivity for Chlamydia pneumoniae or Helicobacter pylori and anti‐oxLDL antibody levels were similar in cases and controls (p = NS). At a 4‐month control, simvastatin reduced CRP levels (p = 0.009) while placebo did not (p = NS). However, the risk of death associated with high baseline CRP levels was similar in patients randomized to placebo (OR = 2.36, 95% CI 1.06‐5.26) or simvastatin (OR = 3.13, 95% CI 1.06‐9.21).
Conclusions: Elevated CRP levels, but not seropositivity for Chlamydia pneumoniae or Helicobacter pylori, nor levels of anti‐oxLDL antibodies, predict the risk of death in patients with stable ischemic heart disease. Simvastatin treatment reduces CRP levels, but without affecting the increased risk conferred by higher CRP levels at baseline.
Keywords: lipids, mortality, infection, inflammation, coronary disease
Full Text
The Full Text of this article is available as a PDF (56.6 KB).
References
- 1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336 (14): 973–979 [DOI] [PubMed] [Google Scholar]
- 2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C‐reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97 (5): 425–428 [DOI] [PubMed] [Google Scholar]
- 3. Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C‐reactive protein and coronary heart disease in the MRFIT nested case‐control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144 (6): 537–547 [DOI] [PubMed] [Google Scholar]
- 4. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH: Relationship of C‐reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17 (6): 1121–1127 [DOI] [PubMed] [Google Scholar]
- 5. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332 (10): 635–641 [DOI] [PubMed] [Google Scholar]
- 6. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C‐reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349 (9050): 462–466 [DOI] [PubMed] [Google Scholar]
- 7. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C‐reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331 (7): 417–424 [DOI] [PubMed] [Google Scholar]
- 8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 (20): 1301–1307 [DOI] [PubMed] [Google Scholar]
- 9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease : The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383–1389 [PubMed] [Google Scholar]
- 10. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moyé LA, Goldman S, Fiacker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98 (9): 839–844 [DOI] [PubMed] [Google Scholar]
- 11. Cuthbert JA, Lipsky PE: Sterol metabolism and lymphocyte responsiveness: Inhibition of endogenous sterol synthesis prevents mitogen‐induced human T cell proliferation. J Immunol 1981; 126 (6): 2093–2099 [PubMed] [Google Scholar]
- 12. Cutts JL, Bankhurst AD: Suppression of lymphoid cell function in vitro by inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989; 11 (8): 863–869 [DOI] [PubMed] [Google Scholar]
- 13. Weber C, Erl W, Weber KS, Weber PC: HMG‐CoA reductase inhibitors decrease CD11b expression and CD11b‐ dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30 (5): 1212–1217 [DOI] [PubMed] [Google Scholar]
- 14. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manniken V, Manttari M, Frick MH, Huttunen JK: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116 (4): 273–278 [DOI] [PubMed] [Google Scholar]
- 15. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96 (2): 404–407 [DOI] [PubMed] [Google Scholar]
- 16. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B: Randomised trial of roxithromycin in non‐Q‐wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350 (9075): 404–407 [DOI] [PubMed] [Google Scholar]
- 17. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ, Northfield TC: Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J 1995; 311 (7007): 711–714 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Mendall MA, Goggin PM, Molineaux N, Levi J, Toosy T, Strachan D, Camm AJ, Northfield TC: Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71 (5): 437–439 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Maggi E, Perani G, Falaschi F, Frattoni A, Martignoni A, Finardi G, Stefano PL, Simeone F, Paolini G, DeVecchi E, Grossi A, Bellomo G: Autoantibodies against oxidised low density lipoproteins in patients with coronary disease. Presse Med 1994; 23 (25): 1158–1162 [PubMed] [Google Scholar]
- 20. Maggi E, Finardi G, Poli M, Bollati P, Filipponi M, Stefano PL, Paolini G, Grossi A, Clot P, Albano E: Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 1993; 4 (12): 1119–1122 [DOI] [PubMed] [Google Scholar]
- 21. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G: Presence of autoantibodies against oxidatively modified low‐density lipoprotein in essential hypertension: A biochemical signature of an enhanced in vivo low‐density lipoprotein oxidation. J Hypertens 1995; 13 (1): 129–138 [PubMed] [Google Scholar]
- 22. Seccia M, Albano E, Maggi E, Bellomo G: Circulating autoanti‐bodies recognizing peroxidase‐oxidized low density lipoprotein. Evidence for new antigenic epitopes formed in vivo independently from lipid peroxidation. Arterioscler Thromb Vasc Biol 1997; 17 (1): 134–140 [DOI] [PubMed] [Google Scholar]
- 23. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S: C‐reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q‐wave acute myocardial infarction. Circulation 1997; 96 (3): 778–784 [DOI] [PubMed] [Google Scholar]
- 24. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G: Dual control of C‐reactive protein gene expression by interleukin‐1 and interleukin‐6. Embo J 1989; 8 (12): 3773–3779 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bitzet J, Limburg PL, Aarden LA, van Ritswijk MH: Tumor necrosis factor (TNF) inhibits interleukin (IL)‐1 and/or IL‐6 stimulated synthesis of C‐reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1991; 1091 (3): 405–408 [DOI] [PubMed] [Google Scholar]
- 26. Bevilacqua MP, Gimbrone MA Jr: Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost 1987; 13 (4): 425–433 [DOI] [PubMed] [Google Scholar]
- 27. Lee RT, Libby P: The unstable atheroma. Arterioscler Thromb Vasc Biol 1997; 17 (10): 1859–1867 [DOI] [PubMed] [Google Scholar]
- 28. Zeiher AM, Goebel H, Schachinger V, Ihling C: Tissue endothelin‐1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995; 91 (4): 941–947 [DOI] [PubMed] [Google Scholar]
- 29. Ross RM, Young JA: Clinical and necropsy finding in rupture of the myocardium: A review of forty‐three cases. Scott Med J 1963; 8: 222–226 [DOI] [PubMed] [Google Scholar]
- 30. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH: Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99 (9): 1161–1164 [DOI] [PubMed] [Google Scholar]
- 31. Monaco C, Crea F, Niccoli G, Summaria F, Cianflone D, Bordone R, Bellomo G, Maseri A: Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease: Pathophysiological implications. Eur Heart J 2001; 22 (17): 1572–1577 [DOI] [PubMed] [Google Scholar]
- 32. The Cholesterol and Recurrent Events (CARE) Investigators : Long‐term effects of pravastatin on plasma concentration of C‐reactive protein. Circulation 1999; 20: 100(3): 230–235 [DOI] [PubMed] [Google Scholar]
- 33. Ridker PM, Rifai N, Clearfield M, Downs J, Weis SE, Miles JS, Gotto A: Measurements of C‐reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344 (26): 1959–1965 [DOI] [PubMed] [Google Scholar]